Advancing new drug therapies for unmet medical needs

Developing novel drug therapies for unmet medical needs 2018-02-05T09:26:29+00:00

Dimerix Limited is a clinical stage biotechnology company that is listed on the Australian Stock Exchange (ASX:DXB)

Our vision is to positively improve human health by creating safe and effective new treatments for patients with unmet medical needs

Recent news and media

ASX: Gold Coast Investor Showcase presentation

Dimerix CEO Kathy Harrison will be presenting at the Gold Coast Investor Showcase today (20 June 2018). An updated presentation is [...]

Analyst coverage: Bioshares update 18 May 2018

Bioshares have published a summary of the recent activities and program developments at Dimerix. The report is available here.

Powerful Trial Design to Lead Next Stage DMX-200 Chronic Kidney Disease Subgroup Studies

Highlights  • Dimerix to launch next stage of lead program, DMX-200, with two simultaneous Phase 2 clinical trials in the area [...]

Click here to view analyst coverage
Click here to view our corporate fact sheet
Click here to view our corporate presentation